PineTree Therapeutics

Pinetree Therapeutics, Inc. is a preclinical-stage biotechnology company headquartered at West Cambridge Scientific Park, 767C Concord Ave, Cambridge, Massachusetts, developing next-generation targeted protein degraders (TPDs) built on its proprietary AbReptor platform. AbReptor degrades membrane-bound and extracellular proteins through target co-engagement, induced endocytosis, endolysosome formation and lysosomal degradation, aiming to overcome drug resistance and tumor recurrence in oncology, with additional application in inflammation and immunology. The company is advancing trispecific degraders and ADC-integrated programs, closed a $17M Series A in July 2024, and has entered a licensing partnership with AstraZeneca. It is a therapeutics developer rather than a software vendor: it publishes no public API, developer portal, SDK or machine-readable specification.

PineTree Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Oncology.

PineTree Therapeutics’ developer surface includes product news and 8 more developer resources.

🌐 Visit website 📡 Source on GitHub

5.4/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0

0 APIs

CompanyBiotechnologyPharmaceuticalsLife SciencesOncologyDrug DiscoveryTargeted Protein DegradationPreclinical

Kin Score

Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0

Composite quality — 5.4/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Commercial Clarity 0.0 / 17

Operational Transparency 0.0 / 11

Governance 0.0 / 10

Discoverability 4.3 / 9

Regulatory Posture 1.1 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/pinetree-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Contact

Contact

Company 5

The organization behind the API

Website

News

Careers

Investors

LinkedIn

Other 2

Properties that don't map to a standard resource type

Team

Team

SecondaryMarket

SecondaryMarket

Source (apis.yml)

aid: pinetree-therapeutics
name: PineTree Therapeutics
description: 'Pinetree Therapeutics, Inc. is a preclinical-stage biotechnology company headquartered at West Cambridge Scientific
  Park, 767C Concord Ave, Cambridge, Massachusetts, developing next-generation targeted protein degraders (TPDs) built on
  its proprietary AbReptor platform. AbReptor degrades membrane-bound and extracellular proteins through target co-engagement,
  induced endocytosis, endolysosome formation and lysosomal degradation, aiming to overcome drug resistance and tumor recurrence
  in oncology, with additional application in inflammation and immunology. The company is advancing trispecific degraders
  and ADC-integrated programs, closed a $17M Series A in July 2024, and has entered a licensing partnership with AstraZeneca.
  It is a therapeutics developer rather than a software vendor: it publishes no public API, developer portal, SDK or machine-readable
  specification.'
image: https://www.pinetreetx.com/images/common/logo.png
url: https://raw.githubusercontent.com/api-evangelist/pinetree-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-05'
modified: '2026-08-05'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Oncology
- Drug Discovery
- Targeted Protein Degradation
- Preclinical
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/pinetree-therapeutics-domain-security.yml
- type: Website
  url: https://www.pinetreetx.com/
- type: News
  url: https://www.pinetreetx.com/en/news/news.php
- type: Team
  url: https://www.pinetreetx.com/en/team/leadership.php
- type: Careers
  url: https://www.pinetreetx.com/en/careers/job.php
- type: Investors
  url: https://www.pinetreetx.com/en/investors/investors.php
- type: Contact
  url: https://www.pinetreetx.com/en/communication/contact.php
- type: SecondaryMarket
  url: https://forgeglobal.com/pinetree-therapeutics_stock/
- type: LinkedIn
  url: https://www.linkedin.com/company/pinetree-therapeutics
x-enrichment:
  date: '2026-08-05'
  status: minimal
  artifacts_added: 1
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Pinetree Therapeutics is a preclinical-stage oncology drug developer whose product is a protein-degrader therapeutic,
    not software — its entire public site is seven brochure pages (team, science, news, careers, investors, contact) served
    from PHP with no /developers, /api, api./docs./developer. subdomain, sitemap, llms.txt or any /.well-known/ document.
  evidence:
  - url: https://www.pinetreetx.com/
    status: 200
  - url: https://www.pinetreetx.com/developers
    status: 404
  - url: https://www.pinetreetx.com/api
    status: 404
  - url: https://www.pinetreetx.com/openapi.json
    status: 404
  - url: https://www.pinetreetx.com/llms.txt
    status: 404
  - url: https://www.pinetreetx.com/.well-known/agent-card.json
    status: 404
  - url: https://www.pinetreetx.com/.well-known/security.txt
    status: 404
  checked: '2026-08-05'